FIRST APPROVAL FOR NYCOMED'S ABDOSCAN
The Swedish authorities have granted Hafslund Nycomed marketing authorization for its new oral magnetic resonance imaging agent, Abdoscan (oral magnetic particles). The product is intended for detection of diseases in the gastrointestinal tract, particularly tumors.
Hafslund Nycomed intends Abdoscan to be used both on its own and in combination with its Omniscan (gadodiamide) product to provide an enhanced MR image of the abdominal cavity and pelvic region. The company is seeking approval in other European countries, the Middle East and the Far East. In the USA, Abdoscan is being developed exclusively by Sterling Winthrop, and is currently in Phase I/II trials.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze